Physician profile
Alejandro L Martinez
NPI 1114141132
$1,601.72
in general payments reported to CMS, 2019-2025
20 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $342 · 2021: $282 · 2022: $194 · 2023: $183 · 2024: $196 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $284.19 | 2020-2024 | Emgality, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $253.68 | 2019-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $204.65 | 2019-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $180.37 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $162.04 | 2022-2025 | |
| Pfizer INC. | $102.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.90 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $60.50 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $50.79 | 2020-2022 | |
| Amgen INC. | $31.12 | 2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $25.18 | 2023 | Xarelto |
| Astellas Pharma US INC | $22.66 | 2019-2020 | |
| Dexcom, INC. | $20.64 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $19.81 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.68 | 2025 | Xifaxan |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $16.35 | 2020 | |
| Abbott Laboratories | $16.24 | 2019 | |
| Boston Scientific Corporation | $14.95 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.60 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.